bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
AGBMA

Order Name:
Anti Glomerular Basement Membrane (Anti GBM)

 
Useful For:
Diagnosis of Goodpasture syndrome in the suspected patient.
 
Methodology:
Enzyme-linked Immunosorbent Assay (ELISA)
 
AliasesName:
Anti-GBM (Glomerular Basement Membrane)
Antiglomerular Basement Membrane Antibody-IgG
Basement Membrane Antibody
Basement Membrane, Glomerular Antibody
GBM (Glomerular Basement Membrane) Antibody
GBM Antibody
Glomerular Anti-Basement Membrane
Goodpastures Syndrome
 
 
 
Test Code:
AGBMA

Order Name:
Anti Glomerular Basement Membrane (Anti GBM)

 
Collection Specimen Or Container:
Blood/ Plain blood (Red top) 6 mL, 1 tube
 
Specimen Testing Type:
Serum, minimum volume 0.5 mL
 
Sub Mission Container:
Plastic tube
 
Rejection Criteria:
Hemolysis: Mild OK; Gross reject
Lipemia: Mild OK; Gross reject
Icterus: Mild OK; Gross reject
Other: N/A
 
Specimen Stabillity:
Specimen Type Temperature Time
Serum Refrigerated, 2oC to 8oC 14 days
 
 
 
Test Code:
AGBMA

Order Name:
Anti Glomerular Basement Membrane (Anti GBM)

 
Method detail:
Enzyme-linked Immunosorbent Assay (ELISA)
 
Schedule:
Test daily, at 01:00 p.m.
 
Turnaround Time:
Received specimen to reported within 2 days.
 
Performing Location:
Molecular biology & Genetics, Laboratory Department Tel.14168
 
Specimen Retention Time:
7 days
 
 
 
Test Code:
AGBMA

Order Name:
Anti Glomerular Basement Membrane (Anti GBM)

 
 
Clinical Information:
Autoantibodies against glomerular basement membrane (GBM) can be serologically detected in Anti-GBM disease, a glomerular nephritis which frequently involves the lungs (then called Goodpasture syndrome). Approximately 10% of the patients with GBM antibodies also show additional MPO ANCA. Goodpasture syndrome is characterised by bloody secretion and may lead to lung siderosis. Without treatment the syndrome has a very poor prognosis. Since the disease progresses rapidly, early diagnosis is imperative and can be confirmed by the detection of anti-GBM antibodies.
 
Reference Value:
< 20 RU/mL
 
Interpretation:
Autoantibodies to glomerular basement membranes (GBM) are highly specific and sensitive markers for Goodpasture’s syndrome. The prevalence of GBM antibodies in patients with lung involvement amounts to 80-90%, in patients without lung involvement to 60%. GBM antibodies have shown to be crucial for an early diagnosis of the disease. Since the clinical progression of the disease correlates with antibody concentration, with high-titers indicating an unfavourable prognosis, ELISA-based quantification of GBM autoantibodies enables a monitoring of the course of disease. A regular,quantitative determination of the autoantibody titer supports the monitoring of the therapy success, since the titer correlates with the disease activity.
 
Clinical Reference:
Manufacturer’s reagent package insert, Anti-GBM ELISA (IgG) Test instruction, August 2016, EUROIMMUN, Lübeck, D-23560 Germany.